Belite Bio Inc. (BLTE) just made history in a corner of medicine that desperately needed some good news. The company announced Monday that its Phase 3 DRAGON trial hit the mark for Tinlarebant, making it the first drug to successfully complete a pivotal trial for Stargardt disease type 1.
If you haven't heard of Stargardt disease, you're not alone. It's a rare genetic eye condition that causes progressive vision loss, typically showing up during childhood or young adulthood. Not exactly the kind of thing that gets a lot of research funding or pharma attention, which makes this result particularly meaningful for the roughly 30,000 people estimated to have it in the United States.
The trial enrolled 104 patients and tested whether Tinlarebant could slow down the disease's progression. Here's the science in plain English: Stargardt disease involves the buildup of vitamin A-based toxins called bisretinoids in the retina. These nasty byproducts accumulate because of the eye's normal visual cycle, which depends on vitamin A to function.
Tinlarebant tackles this by reducing levels of retinol binding protein 4, or RBP4 for short. Think of RBP4 as the delivery truck that carries vitamin A from your liver to your eyes. By keeping those RBP4 levels down, the drug limits how much vitamin A reaches the eye, which in turn reduces the formation of those toxic bisretinoids.
The results look solid across the board. Tinlarebant hit the primary endpoint with a statistically significant 35.7% reduction in lesion growth rate compared to placebo, with a p-value of 0.0033. The fellow eye (the non-primary eye being tracked) showed similar results with a 33.6% reduction in lesion growth.
The drug also slowed what researchers call decreased autofluorescence lesion growth by 33.7% in the study eye and 32.7% in the fellow eye. These are different ways of measuring the same basic problem: damage spreading across the retina.
On the safety front, the 5 mg daily dose managed to knock down RBP4 levels by about 80% compared to baseline. When patients stopped taking the drug, those levels bounced back to 84% of baseline within one to three months, which is reassuring from a safety perspective. The drug was well-tolerated overall, with only four patients discontinuing treatment due to side effects.
One interesting note: visual acuity didn't change much over the 24-month trial period in either group, but that's actually expected given how Stargardt disease progresses. The damage is happening at the cellular level in ways that don't immediately translate to measurable vision loss over this timeframe, which matches what natural history studies have shown.
Belite Bio now plans to meet with regulatory authorities about next steps and aims to submit New Drug Applications for Tinlarebant in the first half of 2026. If approved, this would be the first treatment option for a disease that currently has none.
The market liked what it heard. BLTE stock jumped 11.3% to $153.05 in premarket trading Monday following the announcement.
